Cornelia Haag-Molkenteller
Direttore Tecnico/Scientifico/R&S presso UROVANT SCIENCES LTD.
Posizioni attive di Cornelia Haag-Molkenteller
Società | Posizione | Inizio | Fine |
---|---|---|---|
UROVANT SCIENCES LTD. | Direttore Tecnico/Scientifico/R&S | 01/04/2018 | - |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Direttore Tecnico/Scientifico/R&S | 01/04/2018 | - |
Storia della carriera di Cornelia Haag-Molkenteller
Precedenti posizioni note di Cornelia Haag-Molkenteller
Società | Posizione | Inizio | Fine |
---|---|---|---|
ALLERGAN PLC | Corporate Officer/Principal | 01/11/2007 | 01/03/2018 |
Schwarz BioSciences GmbH | Corporate Officer/Principal | 01/01/1988 | 01/01/2006 |
Formazione di Cornelia Haag-Molkenteller
Johann Wolfgang Goethe-Universität Frankfurt am Main | Doctorate Degree |
Statistiche
Distribuzione geografica
Germania | 3 |
Irlanda | 2 |
Stati Uniti | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
Allergan Ltd. (Ireland)
Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
Schwarz BioSciences GmbH | |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Health Technology |
Urovant Sciences Ltd.
Urovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom. | Health Technology |